TrialJournal of neurology2023

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.

Andreas Meisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.